Paper4561966
Mechanism of the antitumour effect of interferon in mice.
Gresser I and 2 others. Nature, 1972. Cited by 266 papers, by iCite.
Cite this record
ConductScience Library. Mechanism of the antitumour effect of interferon in mice. Papers, record 4561966. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4561966
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Interferons | Major topic |
| Leukemia L1210 | Major topic |
| Animals | |
| Cell Division | |
| Mice | |
| Mice, Inbred DBA | |
| Neoplasm Transplantation |
Source PubMed
Cited by51
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 266 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42098864 | Reduction of primary tumor growth and metastasis in models of triple-negative breast cancer following tilorone administration via type I interferon signaling. | Breast Cancer Res | 2026 | https://conductscience.org/library/papers/42098864 | PubMed |
| 36090998 | The gamble between oncolytic virus therapy and IFN. | Front Immunol | 2022 | https://conductscience.org/library/papers/36090998 | PubMed |
| 35251003 | Role of Hypoxia in the Interferon Response. | Front Immunol | 2022 | https://conductscience.org/library/papers/35251003 | PubMed |
| 34571733 | The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation. | Biology (Basel) | 2021 | https://conductscience.org/library/papers/34571733 | PubMed |
| 33922087 | Functional Interfaces, Biological Pathways, and Regulations of Interferon-Related DNA Damage Resistance Signature (IRDS) Genes. | Biomolecules | 2021 | https://conductscience.org/library/papers/33922087 | PubMed |
| 33842331 | Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. | Front Oncol | 2021 | https://conductscience.org/library/papers/33842331 | PubMed |
| 33408718 | Context Is Key: Delineating the Unique Functions of IFNα and IFNβ in Disease. | Front Immunol | 2020 | https://conductscience.org/library/papers/33408718 | PubMed |
| 31900802 | Retained or altered expression of major histocompatibility complex class I in patient-derived xenograft models in breast cancer. | Immunol Res | 2019 | https://conductscience.org/library/papers/31900802 | PubMed |
| 31771762 | Interferon signaling in cancer. Non-canonical pathways and control of intracellular immune checkpoints. | Semin Immunol | 2019 | https://conductscience.org/library/papers/31771762 | PubMed |
| 30528455 | Concomitant type I IFN and M-CSF signaling reprograms monocyte differentiation and drives pro-tumoral arginase production. | EBioMedicine | 2019 | https://conductscience.org/library/papers/30528455 | PubMed |
| 28798748 | Role of Type I and II Interferons in Colorectal Cancer and Melanoma. | Front Immunol | 2017 | https://conductscience.org/library/papers/28798748 | PubMed |
| 28638743 | Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. | Oncoimmunology | 2017 | https://conductscience.org/library/papers/28638743 | PubMed |
| 26911188 | Antitumour actions of interferons: implications for cancer therapy. | Nat Rev Cancer | 2016 | https://conductscience.org/library/papers/26911188 | PubMed |
| 24400008 | Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response. | Front Immunol | 2013 | https://conductscience.org/library/papers/24400008 | PubMed |
| 19710501 | CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. | Blood | 2009 | https://conductscience.org/library/papers/19710501 | PubMed |
| 17522764 | Interferon-beta inhibits liver metastases from murine colon 26 carcinoma and its highly metastatic variant. | Surg Today | 2007 | https://conductscience.org/library/papers/17522764 | PubMed |
| 12622455 | A phase II study of radiotherapy after hyperbaric oxygenation combined with interferon-beta and nimustine hydrochloride to treat supratentorial malignant gliomas. | J Neurooncol | 2003 | https://conductscience.org/library/papers/12622455 | PubMed |
| 11778967 | Apoptosis and cell growth inhibition as antitumor effector functions of interferons. | Med Oncol | 2001 | https://conductscience.org/library/papers/11778967 | PubMed |
| 11131987 | Initial and maintenance combination treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma. | J Neurooncol | 2000 | https://conductscience.org/library/papers/11131987 | PubMed |
| 8919284 | Rapid growth of hepatocellular carcinoma after or during interferon treatment of chronic hepatitis C: report of three cases. | Surg Today | 1996 | https://conductscience.org/library/papers/8919284 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4561966
GET https://conductscience.org/api/papers/v1/4561966/cited_by?page=2